{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T09:43:28Z","timestamp":1785059008688,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04226-6","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:13:14Z","timestamp":1769490794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Empowering exhausted T cells of Glioblastoma patients by Neurotransmitters and Neuropeptides: decreasing immune checkpoint inhibitors, and increasing CD3zeta, proliferation and Glioblastoma arrest"],"prefix":"10.1007","volume":"75","author":[{"given":"Mia","family":"Levite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nili","family":"Ilouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eithan","family":"Galun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigal","family":"Shoshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"7","key":"4226_CR1","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1158\/1078-0432.CCR-18-1625","volume":"25","author":"BD Choi","year":"2019","unstructured":"Choi BD, Maus MV, June CH, Sampson JH (2019) Immunotherapy for glioblastoma: adoptive T-cell strategies. Clin Cancer Res 25(7):2042\u20132048","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4226_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.trecan.2022.12.008","volume":"9","author":"MB Watowich","year":"2023","unstructured":"Watowich MB, Gilbert MR, Larion M (2023) T cell exhaustion in malignant gliomas. Trends Cancer 9(4):270\u2013292","journal-title":"Trends Cancer"},{"issue":"17","key":"4226_CR3","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","volume":"24","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH et al (2018) T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res 24(17):4175\u20134186","journal-title":"Clin Cancer Res"},{"issue":"17","key":"4226_CR4","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1158\/1078-0432.CCR-17-2617","volume":"24","author":"M Mohme","year":"2018","unstructured":"Mohme M, Schliffke S, Maire CL, Runger A, Glau L, Mende KC et al (2018) Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes. Clin Cancer Res 24(17):4187\u20134200","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4226_CR5","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/1078-0432.CCR-18-1176","volume":"25","author":"TB Davidson","year":"2019","unstructured":"Davidson TB, Lee A, Hsu M, Sedighim S, Orpilla J, Treger J et al (2019) Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. Clin Cancer Res 25(6):1913\u20131922","journal-title":"Clin Cancer Res"},{"issue":"82","key":"4226_CR6","doi-asserted-by":"publisher","first-page":"35287","DOI":"10.18632\/oncotarget.26228","volume":"9","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka K, Fecci PE (2018) T-cell exhaustion in glioblastoma. Oncotarget 9(82):35287\u201335288","journal-title":"Oncotarget"},{"issue":"16","key":"4226_CR7","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","volume":"24","author":"KI Woroniecka","year":"2018","unstructured":"Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE (2018) T-cell dysfunction in glioblastoma: applying a new framework. Clin Cancer Res 24(16):3792\u20133802","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4226_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry EJ (2011) T cell exhaustion. Nat Immunol 12(6):492\u2013499","journal-title":"Nat Immunol"},{"key":"4226_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.617658","author":"M Levite","year":"2021","unstructured":"Levite M (2021) T cells plead for rejuvenation and amplification; With the brain\u2019s neurotransmitters and neuropeptides we can make it happen. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.617658","journal-title":"Front Immunol"},{"key":"4226_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-014-1242-y","author":"S Saussez","year":"2014","unstructured":"Saussez S, Laumbacher B, Chantrain G, Rodriguez A, Gu S, Wank R et al (2014) Towards neuroimmunotherapy for cancer: the neurotransmitters glutamate, dopamine and GnRH-II augment substantially the ability of T cells of few head and neck cancer patients to perform spontaneous migration, chemotactic migration and migration towards the autologous tumor, and also elevate markedly the expression of CD3zeta and CD3epsilon TCR-associated chains. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-014-1242-y","journal-title":"J Neural Transm"},{"key":"4226_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2021.102159","volume":"89","author":"M Levite","year":"2021","unstructured":"Levite M, Safadi R, Milgrom Y, Massarwa M, Galun E (2021) Neurotransmitters and neuropeptides decrease PD-1 in T cells of healthy subjects and patients with hepatocellular carcinoma (HCC), and increase their proliferation and eradication of HCC cells. Neuropeptides 89:102159","journal-title":"Neuropeptides"},{"issue":"6","key":"4226_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/10428190902878448","volume":"50","author":"Y Ganor","year":"2009","unstructured":"Ganor Y, Grinberg I, Reis A, Cooper I, Goldstein RS, Levite M (2009) Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147\/EMMPRIN, MMP-9 secretion and engraftment of T-leukemia in vivo. Leuk Lymphoma 50(6):985\u2013997","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"4226_CR13","doi-asserted-by":"publisher","first-page":"12544","DOI":"10.1073\/pnas.95.21.12544","volume":"95","author":"M Levite","year":"1998","unstructured":"Levite M (1998) Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci U S A 95(21):12544\u201312549","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"4226_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/nm1202-801","volume":"8","author":"A Chen","year":"2002","unstructured":"Chen A, Ganor Y, Rahimipour S, Ben-Aroya N, Koch Y, Levite M (2002) The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat Med 8(12):1421\u20131426","journal-title":"Nat Med"},{"issue":"8","key":"4226_CR15","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.4049\/jimmunol.170.8.4362","volume":"170","author":"Y Ganor","year":"2003","unstructured":"Ganor Y, Besser M, Ben-Zakay N, Unger T, Levite M (2003) Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J Immunol 170(8):4362\u20134372","journal-title":"J Immunol"},{"issue":"4","key":"4226_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1084\/jem.192.4.557","volume":"192","author":"AW Goldrath","year":"2000","unstructured":"Goldrath AW, Bogatzki LY, Bevan MJ (2000) Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med 192(4):557\u2013564","journal-title":"J Exp Med"},{"issue":"6","key":"4226_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.immuni.2008.11.002","volume":"29","author":"CD Surh","year":"2008","unstructured":"Surh CD, Sprent J (2008) Homeostasis of naive and memory T cells. Immunity 29(6):848\u2013862","journal-title":"Immunity"},{"issue":"3","key":"4226_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.immuni.2017.02.010","volume":"46","author":"H Tan","year":"2017","unstructured":"Tan H, Yang K, Li Y, Shaw TI, Wang Y, Blanco DB et al (2017) Integrative proteomics and phosphoproteomics profiling reveals dynamic signaling networks and bioenergetics pathways underlying T cell activation. Immunity 46(3):488\u2013503","journal-title":"Immunity"},{"issue":"8","key":"4226_CR19","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41590-020-0714-5","volume":"21","author":"T Wolf","year":"2020","unstructured":"Wolf T, Jin W, Zoppi G, Vogel IA, Akhmedov M, Bleck CKE et al (2020) Dynamics in protein translation sustaining T cell preparedness. Nat Immunol 21(8):927\u2013937","journal-title":"Nat Immunol"},{"issue":"6","key":"4226_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ni0608-583","volume":"9","author":"B Malissen","year":"2008","unstructured":"Malissen B (2008) CD3 ITAMs count! Nat Immunol 9(6):583\u2013584","journal-title":"Nat Immunol"},{"issue":"10","key":"4226_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-004-0521-0","volume":"53","author":"TL Whiteside","year":"2004","unstructured":"Whiteside TL (2004) Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53(10):865\u2013878","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4226_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ijc.26355","volume":"131","author":"JD Boniface","year":"2012","unstructured":"Boniface JD, Poschke I, Mao Y, Kiessling R (2012) Tumor-dependent down-regulation of the zeta-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 131(1):129\u2013139","journal-title":"Int J Cancer"},{"issue":"1","key":"4226_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10555-005-5050-6","volume":"24","author":"TL Whiteside","year":"2005","unstructured":"Whiteside TL (2005) Immunobiology of head and neck cancer. Cancer Metastasis Rev 24(1):95\u2013105","journal-title":"Cancer Metastasis Rev"},{"issue":"12","key":"4226_CR24","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.4049\/jimmunol.163.12.6912","volume":"163","author":"C Maccalli","year":"1999","unstructured":"Maccalli C, Pisarra P, Vegetti C, Sensi M, Parmiani G, Anichini A (1999) Differential loss of T cell signaling molecules in metastatic melanoma patients\u2019 T lymphocyte subsets expressing distinct TCR variable regions. J Immunol 163(12):6912\u20136923","journal-title":"J Immunol"},{"issue":"11","key":"4226_CR25","first-page":"1327","volume":"1","author":"AH Zea","year":"1995","unstructured":"Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H et al (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin cancer res offi j American Assoc Cancer Res 1(11):1327\u20131335","journal-title":"Clin cancer res offi j American Assoc Cancer Res"},{"issue":"6","key":"4226_CR26","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/ijc.2910590607","volume":"59","author":"F Farace","year":"1994","unstructured":"Farace F, Angevin E, Vanderplancke J, Escudier B, Triebel F (1994) The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration. Int J Cancer 59(6):752\u2013755","journal-title":"Int J Cancer"},{"issue":"23","key":"4226_CR27","first-page":"5610","volume":"53","author":"H Nakagomi","year":"1993","unstructured":"Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H et al (1993) Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53(23):5610\u20135612","journal-title":"Cancer Res"},{"issue":"5\u20136","key":"4226_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/10428199909169619","volume":"35","author":"I Frydecka","year":"1999","unstructured":"Frydecka I, Kaczmarek P, Bocko D, Kosmaczewska A, Morilla R, Catovsky D (1999) Expression of signal-transducing zeta chain in peripheral blood T cells and natural killer cells in patients with Hodgkin\u2019s disease in different phases of the disease. Leuk Lymphoma 35(5\u20136):545\u2013554","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"4226_CR29","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4161\/epi.22675","volume":"7","author":"JK Wiencke","year":"2012","unstructured":"Wiencke JK, Accomando WP, Zheng S, Patoka J, Dou X, Phillips JJ et al (2012) Epigenetic biomarkers of T-cells in human glioma. Epigenetics 7(12):1391\u20131402","journal-title":"Epigenetics"},{"issue":"3","key":"4226_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170\u2013186","journal-title":"Nat Rev Clin Oncol"},{"key":"4226_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910765","author":"SMB Rodriguez","year":"2024","unstructured":"Rodriguez SMB, Tataranu LG, Kamel A, Turliuc S, Rizea RE, Dricu A (2024) Glioblastoma and immune checkpoint inhibitors: a glance at available treatment options and future directions. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms251910765","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4226_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aar2766","volume":"4","author":"FL Ricklefs","year":"2018","unstructured":"Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H et al (2018) Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv 4(3):eaar2766","journal-title":"Sci Adv"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04226-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04226-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04226-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:13:15Z","timestamp":1769490795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04226-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4226"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04226-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study on T cells of Glioblastoma patients complies with the ethical guidelines and has an IRB approval No. 0482\u201321-HMO from Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical aproval"}},{"value":"All the Glioblastoma patients signed informed consents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"54"}}